Your browser doesn't support javascript.
loading
Treating juvenile idiopathic arthritis to target: recommendations of an international task force.
Ravelli, Angelo; Consolaro, Alessandro; Horneff, Gerd; Laxer, Ronald M; Lovell, Daniel J; Wulffraat, Nico M; Akikusa, Jonathan D; Al-Mayouf, Sulaiman M; Antón, Jordi; Avcin, Tadej; Berard, Roberta A; Beresford, Michael W; Burgos-Vargas, Ruben; Cimaz, Rolando; De Benedetti, Fabrizio; Demirkaya, Erkan; Foell, Dirk; Itoh, Yasuhiko; Lahdenne, Pekka; Morgan, Esi M; Quartier, Pierre; Ruperto, Nicolino; Russo, Ricardo; Saad-Magalhães, Claudia; Sawhney, Sujata; Scott, Christiaan; Shenoi, Susan; Swart, Joost F; Uziel, Yosef; Vastert, Sebastiaan J; Smolen, Josef S.
Afiliación
  • Ravelli A; Clinica Pediatrica e Reumatologia, Università degli Studi di Genova and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina, Genoa, Italy.
  • Consolaro A; Clinica Pediatrica e Reumatologia, Università degli Studi di Genova and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina, Genoa, Italy.
  • Horneff G; Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany.
  • Laxer RM; Department of Pediatric and Adolescents Medicine, University Hospital of Cologne, Cologne, Germany.
  • Lovell DJ; Division od Rheumatology, University of Toronto and The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Wulffraat NM; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Akikusa JD; Department of Paediatric Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht and University of Utrecht, Utrecht, The Netherlands.
  • Al-Mayouf SM; Rheumatology Unit, Department of General Medicine, The Royal Children's Hospital and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Antón J; Department of Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center and Alfaisal University, Riyadh, Saudi Arabia.
  • Avcin T; Division of Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
  • Berard RA; Department of Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana and Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Beresford MW; Division of Rheumatology, Western University Children's Hospital, London Health Sciences Centre, London, Ontario, Canada.
  • Burgos-Vargas R; Institute of Translational Medicine, University of Liverpool and Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
  • Cimaz R; Rheumatology Department, Hospital General de México Eduardo Liceaga, México City, Mexico.
  • De Benedetti F; Pediatric Rheumatology, Azienda Ospedaliero Universitaria Meyer, Florence, Italy.
  • Demirkaya E; Division of Rheumatology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  • Foell D; Division of Rheumatology, Western University Children's Hospital, London Health Sciences Centre, London, Ontario, Canada.
  • Itoh Y; Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany.
  • Lahdenne P; Department of Pediatrics, Nippon Medical School, Bunkyo City, Japan.
  • Morgan EM; Institute of Clinical Medicine, Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
  • Quartier P; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Ruperto N; Paris-Descartes University, IMAGINE Institute, RAISE 22 National Reference Centre, Necker-Enfants Malades Hospital, Assistance Publique Hopitaux de Paris, Paris, France.
  • Russo R; Clinica Pediatrica e Reumatologia, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, Genoa, Italy.
  • Saad-Magalhães C; Servicio de Inmunología y Reumatología, Hospital de Pediatría Garrahan, Buenos Aires, Argentina.
  • Sawhney S; Reumatologia Pediátrica, São Paulo State University (UNESP), Botucatu, Brazil.
  • Scott C; Department of Rheumatology, ISIC Superspeciality Hospital and Sir Ganga Ram Hospital, New Delhi, India.
  • Shenoi S; Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.
  • Swart JF; Pediatric Rheumatology, Seattle Children's Hospital and Research Center, University of Washington, Seattle, Washington, USA.
  • Uziel Y; Department of Paediatric Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht and University of Utrecht, Utrecht, The Netherlands.
  • Vastert SJ; Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, Kfar-Saba, Israel.
  • Smolen JS; Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.
Ann Rheum Dis ; 77(6): 819-828, 2018 06.
Article en En | MEDLINE | ID: mdl-29643108
ABSTRACT
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a consensus-based, Delphi-like procedure. Although the literature review did not reveal trials that compared a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated development of recommendations. The group agreed on six overarching principles and eight recommendations. The main treatment target, which should be based on a shared decision with parents/patients, was defined as remission, with the alternative target of low disease activity. The frequency and timeline of follow-up evaluations to ensure achievement and maintenance of the target depend on JIA category and level of disease activity. Additional recommendations emphasise the importance of ensuring adequate growth and development and avoiding long-term systemic glucocorticoid administration to maintain the target. All items were agreed on by more than 80% of the members of the Task Force. A research agenda was formulated. The Task Force developed recommendations for treating JIA to target, being aware that the evidence is not strong and needs to be expanded by future research. These recommendations can inform various stakeholders about strategies to reach optimal outcomes for JIA.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Artritis Juvenil Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Ann Rheum Dis Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Artritis Juvenil Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Ann Rheum Dis Año: 2018 Tipo del documento: Article